Website profile

Morningstar

Empowering Investor Success Morningstar Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today. Plus, whether Nvidia is a buy after earnings.

  • 1,350articles · 30d
  • 24+ min agolatest article
  • Aug 14, 2026earliest in window
  • 88%with images · 6 videos
  • 241avg words
articles per day
Categories
  • Economy, Business & Finance 722
  • Finance & Business 712
  • News 402
  • Business & Industrial 151
  • Finance 147
  • Crime, Law & Justice 124
  • Health & Wellness 115
  • Arts, Culture, Entertainment & Media 113

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Morningstar
morningstar.com > news > pr-newswire > 20/26/0910ny44374 > aard-shareholder-alert-aardvark-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-contact-suewallst

AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

3+ day, 2+ hour ago   (572+ words) NEW YORK, Sept. 10, 2026 Sections 11 and 15 of the Securities Act impose liability for registration statements containing untrue statements of material fact. A securities class action alleges Aardvark Therapeutics' IPO paperwork described ARD-101 as "99% restricted to the gut" with "no serious adverse…...

Morningstar
morningstar.com > news > pr-newswire > 20/26/0909ny43229 > levi-korsinsky-reminds-regeneron-pharmaceuticals-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-14-2026-regn

Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN

4+ day, 4+ hour ago   (518+ words) NEW YORK, Sept. 9, 2026 Institutional investors with REGN positions may need to assess alleged clinical-trial disclosure failures that preceded a $102.09 per-share decline from the Class Period high. This notice focuses on fiduciary review, portfolio loss documentation, and lead plaintiff considerations. REGN…...

Morningstar
morningstar.com > news > pr-newswire > 20/26/0806sf20996 > capr-investor-deadline-capricor-therapeutics-inc-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit

CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

1+ mon, 6+ day ago   (375+ words) SAN FRANCISCO, Aug. 6, 2026 SAN FRANCISCO, Aug. 6, 2026 /PRNewswire/ -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now. A securities fraud class action lawsuit has been filed against Capricor, and investors are…...

Morningstar
morningstar.com > news > business-wire > 20/26/0824953188 > class-action-deadline-tonight-faruqi-faruqi-llp-reminds-peabody-energy-investors-of-securities-class-action-lawsuit-deadline-on-august-24-2026

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Peabody Energy Investors of Securities Class Action Lawsuit Deadline on August 24, 2026

2+ week, 5+ day ago   (299+ words) Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Peabody Energy To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Peabody Energy between October 14, 2024 and May 4, 2026 and would…...

Morningstar
morningstar.com > news > pr-newswire > 20/26/0820ny30666 > regn-shareholder-alert-september-14-2026-lead-plaintiff-deadline-in-regeneron-pharmaceuticals-securities-class-action-contact-suewallst

REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class Action - Contact SueWallSt

3+ week, 3+ day ago   (684+ words) NEW YORK, Aug. 20, 2026 This Regeneron analyst reaction focuses on analysts' reassessment of the Phase III Fianlimab-Libtayo Study after a protocol amendment raised concerns about statistical significance and potential impact on Regeneron's pipeline and future growth expectations. NEW YORK, Aug. 20, 2026 /PRNewswire…...